Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

0.2998 -0.0182 (-5.72%)
Streaming Delayed Price Updated: 3:03 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
News headline image
Mereo BioPharma Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Which stocks are most active on Monday? ↗
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Group Plc (NASDAQ:MREO) Beats Q3 2025 EPS Estimates, Maintains Cash Runway into 2027 ↗
Mereo BioPharma (MREO) beat Q3 EPS estimates with a narrower loss. The clinical-stage company has cash into 2027 and key data for its lead drug expected soon. 
Via Chartmill
News headline image
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks ↗
HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.